Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities
Emerging Microbes & Infections·
- DOI
- 10.1080/22221751.2020.1713707
- PMID
- 31985356
- PMCID
- PMC7040474
- OpenAlex
- W3002664025
- Study type
- Journal article
- Publisher
- Informa UK Limited
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Given the limitations of current antiretroviral therapy and absence of a successful vaccine, broadly neutralizing antibodies represent a novel immunotherapy approach for HIV-1 prevention and treatment.
Structured evidence summary
Research question
This review examines the efficacy, challenges, and opportunities associated with broadly neutralizing antibodies as an approach to HIV-1 prevention and treatment.
Study design
This is a narrative review of broadly neutralizing antibodies for HIV-1, synthesizing evidence on their clinical efficacy and immunological mechanisms.
Population and setting
The review discusses bNAbs in HIV-1-infected individuals, with candidates advancing into clinical trials.
Main findings
Broadly neutralizing antibodies have demonstrated certain efficacies in infected individuals and may kill HIV-1-infected cells while engaging host immunity. However, their use faces challenges including transient viral suppression, emergence of resistant viruses during rebound, suboptimal efficacy in cell-to-cell transmission, and uncertain effects on the cell-associated viral reservoir.
Public-health relevance
Given the limitations of current antiretroviral therapy and absence of a successful vaccine, broadly neutralizing antibodies represent a novel immunotherapy approach for HIV-1 prevention and treatment.
Important limitations
This summary is limited to the supplied single-article abstract and metadata. A comprehensive assessment of the strength of evidence, methodological quality of cited studies, and clinical applicability requires access to the full review manuscript.
GIDS interpretation
This article was identified through classifier links to AIDS, transmission dynamics, treatment, and vaccination topics, indicating relevance to HIV therapeutic development and immunological intervention strategies.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.